Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Molecular Profiling for HER2+ Advanced Solid Tumors
Eric Van Cutsem, MD, PhD
David SP Tan, MBBS, PhD, PRCP
James Chih-Hsin Yang, MD, PhD
Kathleen Moore, MD, MS, FASCO
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
Jeffrey V. Matous, MD
Donna Catamero, NP
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
Jonathan Leventhal, MD
Shahnaz Singh-Kandah, NP
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Erica L. Mayer, MD, MPH
Expert Viewpoint: Optimizing Breast Cancer Treatment
William J. Gradishar, MD
Peter Schmid, FRCP, MD, PhD
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
Aparna R. Parikh, MD
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Emerging Treatment Approaches for EBC
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Alan Venook, MD
Management of HR+, HER2- High-Risk EBC
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
Sara Lonardi, MD
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.